{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:42:43Z","timestamp":1774640563731,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"DOI":"10.7759\/cureus.66164","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T09:03:04Z","timestamp":1722848584000},"source":"Crossref","is-referenced-by-count":1,"title":["Combined Immune Therapy Proves Effective in an Advanced Hepatocellular Carcinoma Patient With Poor Liver Reserve: A Case Report"],"prefix":"10.7759","author":[{"given":"Hisashi","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Karube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Koitabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouka","family":"Numata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yamahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56685","article-title":"Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of Wilms' tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and Nivolumab","volume":"16","author":"Nagai H","year":"2024","unstructured":"Nagai H, Karube R. Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of Wilms' tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and Nivolumab. Cureus. 2024, 16:e56685. 10.7759\/cureus.56685","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i17.4275","article-title":"Dendritic cell-based cancer immunotherapy for colorectal cancer","volume":"22","author":"Kajihara M","year":"2016","unstructured":"Kajihara M, Takakura K, Kanai T, et al.. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol. 2016, 22:4275-86. 10.3748\/wjg.v22.i17.4275","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47320","article-title":"WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer. Cureus. 2023, 15:e47320. 10.7759\/cureus.47320","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2023048735","article-title":"NKT-licensed in vivo dendritic cell-based immunotherapy as cellular immunodrugs for cancer treatment","volume":"29","author":"Fujii SI","year":"2024","unstructured":"Fujii SI, Shimizu K. NKT-licensed in vivo dendritic cell-based immunotherapy as cellular immunodrugs for cancer treatment. Crit Rev Oncog. 2024, 29:45-61. 10.1615\/CritRevOncog.2023048735","journal-title":"Crit Rev Oncog"},{"key":"ref5","article-title":"NK, NKT and invariant-NKT cells in tumor draining lymph nodes of patients with breast cancer","volume":"16","author":"Rezaeifard S","year":"2019","unstructured":"Rezaeifard S, Safaei A, Talei A, Faghih Z, Erfani N. NK, NKT and invariant-NKT cells in tumor draining lymph nodes of patients with breast cancer. Iran J Immunol. 2019, 16:291-8.","journal-title":"Iran J Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417634","article-title":"Breakthroughs in cancer immunotherapy: an overview of T cell, NK cell, M\u03c6, and DC-based treatments","volume":"24","author":"Lee S","year":"2023","unstructured":"Lee S, Kim TD. Breakthroughs in cancer immunotherapy: an overview of T cell, NK cell, M\u03c6, and DC-based treatments. Int J Mol Sci. 2023, 24:17634. 10.3390\/ijms242417634","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani FK","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019, 234:1313-25. 10.1002\/jcp.27172","journal-title":"J Cell Physiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109881","article-title":"Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date","volume":"117","author":"Nikoo M","year":"2023","unstructured":"Nikoo M, Rabiee F, Mohebbi H, et al.. Nivolumab plus ipilimumab combination therapy in cancer: current evidence to date. Int Immunopharmacol. 2023, 117:109881. 10.1016\/j.intimp.2023.109881","journal-title":"Int Immunopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA Clinical Practice Guideline on systemic therapy for hepatocellular carcinoma","volume":"162","author":"Su GL","year":"2022","unstructured":"Su GL, Altayar O, O'Shea R, et al.. AGA Clinical Practice Guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022, 162:920-34. 10.1053\/j.gastro.2021.12.276","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi L","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020, 17:725-41. 10.1038\/s41571-020-0413-z","journal-title":"Nat Rev Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh M","year":"2020","unstructured":"Sadeghzadeh M, Bornehdeli S, Mohahammadrezakhani H, et al.. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci. 2020, 254:117580. 10.1016\/j.lfs.2020.117580","journal-title":"Life Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier E","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024, 626:727-36. 10.1038\/s41586-023-06945-1","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li B","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019, 26:3009-25. 10.2174\/0929867324666170804143706","journal-title":"Curr Med Chem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/277474-combined-immune-therapy-proves-effective-in-an-advanced-hepatocellular-carcinoma-patient-with-poor-liver-reserve-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T09:03:08Z","timestamp":1722848588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/277474-combined-immune-therapy-proves-effective-in-an-advanced-hepatocellular-carcinoma-patient-with-poor-liver-reserve-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.66164","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}